Page 17 - Haematologica Vol. 110 - January 2025

PROS AND CONS EDITORIAL Y. Ofran and J.M. Rowe
Figure 2. An abbreviated personalized therapeutic algorithm for patients with acute myeloid leukemia who failed induction or relapsed. AML: acute myeloid leukemia; AlloHSCT: allogeneic hematopoietic stem cell transplantation.
er, additional consideration is needed for those presenting with molecular relapse. Robust data regarding treatment of molecular relapses are available for patients who are NPM1-positive showing promising results with non-intensive regimens, and even with no transplantation.28-30
While prospective randomized studies are crucial, they are difficult to conduct given the narrow window of eligi- ble patients, i.e., those with immediate donor availability, typically matched sibling donors. In the absence of defin- itive prospective studies, the current practice of treating
References
1. Esteve J, Labopin M, Finke J, et al. Allogeneic stem-cell transplantation for patients with de novo acute myeloid leukemia not in complete response: results of a survey from the European Group for Blood and Bone Marrow Transplantation (EBMT). Blood. 2004;104(11):2302.
2. Forman SJ, Rowe JM. The myth of the second remission of
relapsed patients with chemotherapy pre-transplant re- mains, with notable exceptions, a reasonable standard based on a sound rationale and supported by a multitude of retrospective studies.
Disclosures
No conflicts of interest to disclose.
Contributions
Both authors contributed equally.
acute leukemia in the adult. Blood. 2013;121(7):1077-1082. 3. Stelljes M, Middeke JM, Bug G, et al. Remission induction
versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol.
Haematologica | 110 January 2025
9